0
Signin
countryflagUS

18889881171

MSFT 417.14 0.9731% AAPL 229.0 -0.3438% NVDA 119.37 1.5137% GOOGL 163.38 0.989% GOOG 165.11 1.0465% AMZN 178.5 3.7067% META 521.31 0.5963% AVGO 162.82 3.7533% TSLA 214.11 3.7958% TSM 171.7 1.5075% LLY 960.02 2.1081% V 276.37 0.7473% JPM 224.8 1.1656% UNH 590.2 -0.2316% NVO 139.16 1.1926% WMT 77.23 1.0599% LVMUY 149.005 -0.3844% XOM 117.94 -0.1608% LVMHF 745.0 -0.4011% MA 483.34 0.5283%

MedMira Inc

Healthcare US MMIRF

0.0131USD
-(-%)

Last update at 2024-08-30T13:30:00Z

Day Range

0.010.01
LowHigh

52 Week Range

0.010.19
LowHigh

Fundamentals

  • Previous Close 0.01
  • Market Cap57.73M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-1.91496M
  • Revenue TTM0.43M
  • Revenue Per Share TTM0.001
  • Gross Profit TTM -0.51251M
  • Diluted EPS TTM-

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-07-31 2022-07-31 2021-07-31 2020-07-31 2019-07-31
Type yearly yearly yearly yearly yearly
Date 2023-07-31 2022-07-31 2021-07-31 2020-07-31 2019-07-31
Income before tax -2.67566M -1.83157M -0.67580M -2.04539M -2.10645M
Minority interest - - - - -
Net income -2.67566M -1.83158M -0.67580M -2.04539M -2.10645M
Selling general administrative 1.04M 0.73M 0.49M 1.17M 0.91M
Selling and marketing expenses - 0.01M 0.04M 0.04M 0.13M
Gross profit 0.30M 0.30M 1.72M 0.57M 0.42M
Reconciled depreciation 0.21M 0.21M 0.21M 0.19M 0.02M
Ebit - -1.27954M -0.02250M -1.31976M -1.29603M
Ebitda - -1.06724M 0.19M -1.12659M -1.27717M
Depreciation and amortization - 0.21M 0.21M 0.19M 0.02M
Non operating income net other - - - - -
Operating income -1.77814M -1.45322M -0.18423M -1.30016M -1.29603M
Other operating expenses - 2.22M 2.14M 2.22M 1.82M
Interest expense 0.89M 0.55M 0.65M 0.73M 0.81M
Tax provision - - - - -
Interest income - - - - -
Net interest income -0.89752M -0.56203M -0.68169M -0.74523M -0.81041M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 0.17M 0.16M -0.01960M -
Total revenue 0.43M 0.95M 2.14M 0.92M 0.53M
Total operating expenses 2.21M 1.57M 1.72M 1.87M 1.72M
Cost of revenue 0.13M 0.65M 0.42M 0.35M 0.10M
Total other income expense net - -0.37835M -0.49156M -0.74523M -0.81041M
Discontinued operations - - - - -
Net income from continuing ops -2.67566M -1.83157M -0.67580M -2.04539M -2.10645M
Net income applicable to common shares - -1.83158M -0.67580M -2.04539M -2.10645M
Preferred stock and other adjustments - - - - -
Breakdown 2023-07-31 2022-07-31 2021-07-31 2020-07-31 2019-07-31
Type yearly yearly yearly yearly yearly
Date 2023-07-31 2022-07-31 2021-07-31 2020-07-31 2019-07-31
Total assets 3.65M 3.83M 3.89M 3.40M 0.25M
Intangible assets 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Earning assets - - - - -
Other current assets - 0.05M 2.39M 0.08M 0.01M
Total liab 18.68M 16.19M 19.61M 18.96M 13.77M
Total stockholder equity -15.03166M -12.35600M -15.72390M -15.56235M -13.51696M
Deferred long term liab - - - - -
Other current liab - 9.08M 8.36M 6.99M 5.33M
Common stock - 68.35M 63.90M 63.42M 63.42M
Capital stock 68.35M 68.35M 63.90M 63.42M 63.42M
Retained earnings -97.95910M -95.28345M -93.45187M -92.77607M -90.73069M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 0.01M 0.03M -2.30365M 0.40M 0.09M
Cash and equivalents - - - - -
Total current liabilities 15.73M 14.14M 17.41M 15.81M 13.77M
Current deferred revenue - 0.60M 1.20M 1.24M 0.01M
Net debt 7.25M 8.27M 13.84M 11.51M 8.52M
Short term debt - 6.25M 9.34M 8.76M 8.61M
Short long term debt 6.14M 6.10M 9.19M 8.62M 8.61M
Short long term debt total - 8.30M 11.54M 11.91M 8.61M
Other stockholder equity - 14.58M 0.03M 0.01M 2.75M
Property plant equipment - 2.17M 2.31M 2.48M 0.00674M
Total current assets 1.69M 1.66M 1.58M 0.91M 0.25M
Long term investments - - - - -
Net tangible assets - -12.35850M -15.72640M -15.56485M -13.51947M
Short term investments - - - - -
Net receivables 1.26M 1.37M 1.25M 0.21M 0.04M
Long term debt 1.12M 0.04M 0.04M 0.85M -
Inventory 0.18M 0.20M 0.24M 0.22M 0.11M
Accounts payable 3.26M 2.75M 2.70M 2.31M 2.48M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 14.58M 13.79M 13.78M 11.05M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 1.96M 2.17M 2.31M 2.48M 0.00674M
Capital lease obligations 2.01M 2.16M 2.30M 2.44M -
Long term debt total - - - - -
Breakdown 2023-07-31 2022-07-31 2021-07-31 2020-07-31 2019-07-31
Type yearly yearly yearly yearly yearly
Date 2023-07-31 2022-07-31 2021-07-31 2020-07-31 2019-07-31
Investments -0.00127M -0.06972M -0.03655M -0.10188M 0.00334M
Change to liabilities - -0.57187M 0.32M 1.06M 0.13M
Total cashflows from investing activities - -0.06972M -0.03655M -0.10188M 0.00334M
Net borrowings - 0.35M -0.37493M 0.73M 1.03M
Total cash from financing activities 1.25M 1.99M 0.14M 0.73M 1.03M
Change to operating activities - 0.39M 0.70M 0.76M 0.92M
Net income -2.67566M -1.83158M -0.67580M -2.04539M -2.10645M
Change in cash -0.02028M 0.03M -0.40186M 0.31M 0.09M
Begin period cash flow 0.03M 0.00000M 0.40M 0.09M 0.00000M
End period cash flow 0.01M 0.03M 0.00000M 0.40M 0.09M
Total cash from operating activities -1.26775M -1.88396M -0.50464M -0.31590M -0.94113M
Issuance of capital stock 0.00000M 1.67M 0.52M - -
Depreciation 0.21M 0.21M 0.21M 0.19M 0.02M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory 0.02M 0.03M -0.01319M -0.11633M 0.08M
Change to account receivables -0.01117M 0.00056M -1.04286M -0.16867M 0.00912M
Sale purchase of stock - - - - -
Other cashflows from financing activities - 0.53M 0.06M 1.31M 1.16M
Change to netincome - - - - -0.01250M
Capital expenditures 0.00127M 0.07M 0.04M 0.10M 0.10M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.20M -0.26467M -0.03664M 1.54M 1.16M
Stock based compensation - - - - 0.00000M
Other non cash items - - - - -0.01250M
Free cash flow -1.26902M -1.95367M -0.50464M -0.31590M -0.94113M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MMIRF
MedMira Inc		 - -% 0.01 - - 120.91 - 136.96 -37.5591
NVO
Novo Nordisk A/S		 1.64 1.19% 139.16 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.0025 0.0018% 138.74 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 2.54 0.51% 495.89 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 5.76 0.49% 1184.69 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Europe, the Asia Pacific, and internationally. The company offers Reveal HIV that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests, including combination testing solutions for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product to perform preliminary screening of HIV and hepatitis. It also provides Miriad RVF toolkit that facilitates the development and commercialization of rapid diagnostics; and Reveal G4 HIV tests. In addition, the company offers VYRATM TriDemic antigen rapid test that distinguishes the three respiratory viruses, such as SARS-CoV-2, influenza, and respiratory syncytial virus that exhibit similar symptoms. It sells its products through a network of medical distributors and strategic business development partners to customers in various sectors of the healthcare industry, including laboratories, hospitals, point-of-care clinics, governments, aid organizations, and public health agencies. The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. is a subsidiary of MedMira Holding AG.

MedMira Inc

155 Chain Lake Drive, Halifax, NS, Canada, B3S 1B3

Key Executives

Name Title Year Born
Mr. Hermes Chan Co-Founder, CEO, Pres & Director NA
Mr. Markus M. Meile Chief Financial Officer NA
Stewart McKelvey Legal Counsel NA
Dr. Kevin D. Jones Head of Commercialization and Sr. Director of Sales & Marketing 1969

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.